JTJun Takahashi

Jun Takahashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jun Takahashi has a total of 183 co-authors. Here are the top co-authors by number of shared publications:

  • Tetsuhiro Kikuchi

    Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan

    13 shared publications
  • Bumpei Samata

    Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University , Kyoto

    9 shared publications
  • Susumu Miyamoto

    Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan

    9 shared publications
  • Daisuke Doi

    Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan

    8 shared publications
  • Asuka Morizane

    Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan

    7 shared publications
  • Asuka Morizane

    Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan

    6 shared publications

Latest Publications

  • Open Access

    Modeling interregional propagation of α-synuclein in human striatal-midbrain assembloids

    by Kaneyasu Nishimura, Naoya Amimoto, Yuya Sato, Mieko Morishima, Mamoru Sakaibara, Ayana Haratake, Mai Nakano, Naoko Kaneko, Hideaki Yamamoto, Ayumi Hirano-Iwata, et al.

    Parkinson′s disease is characterized by the progressive degeneration of dopaminergic (DA) neurons in the substantia nigra that project to the striatum. Postmortem studies have found that α-synuclein pathology spreads across brain regions in a prion-like manner. Human three-dimensional neural tissues provide experimentally tractable platforms for clarifying the molecular pathology of synucleinopathy that overcome the limitations of postmortem brain studies. In this study, we established a human striatal-midbrain assembloid model enabling spatially and temporally controlled α-synuclein induction after formation of the nigrostriatal pathway within hStrMAs. Human induced pluripotent stem cells (hiPSCs) were differentiated into striatal spheroids and midbrain spheroids, which were fused to reconstruct the nigrostriatal pathway in vitro. Histological, electrophysiological, and single-cell RNA sequencing analyses confirmed the generation of region-specific neuronal populations, including striatal GABAergic neurons and midbrain DA neurons, and demonstrated that distinct forebrain and ventral midbrain identities were preserved within assembloids. To model synucleinopathy, we generated a doxycycline-inducible α-synuclein hiPSC line, permitting selective induction of α-synuclein expression in the striatal region after assembloid formation. Spatially restricted α-synuclein induction resulted in the progressive accumulation of phosphorylated and fibrillar α-synuclein in midbrain DA neurons, indicating interregional propagation through established neural circuits. Transcriptomic analysis of the midbrain region revealed significant downregulation of DA identity and synaptic function genes, suggesting functional impairment of DA neurons following α-synuclein propagation. These findings demonstrate that the human neural circuit architecture contributes to the interregional propagation of α-synuclein pathology. Our controllable human assembloid platform provides a powerful experimental framework for dissecting the mechanisms of pathological protein spread and developing therapeutic strategies targeting molecular pathology in neurodegenerative diseases.


  • Open Access

    Transplantation of Human iPS Cell-derived Cerebral Cortical Neurons Promotes Fine Motor Recovery in a Female Mouse Model of Ischemic Stroke

    by Hokuto Yamashita, Tetsuhiro Kikuchi, Yusaku Kodaka, Daisuke Doi, Megumi Ikeda, Jun Takahashi

    Background: Stroke is a leading global health concern, with cerebral infarction accounting for 62% of cases. Despite advances in acute-phase treatments, functional impairments such as motor deficits remain prevalent. This study investigates the potential of human induced pluripotent stem cell (iPSC)-derived cerebral cortical neurons for neural regeneration and motor function recovery in a female mouse model of ischemic stroke. Methods: Cerebral infarction was induced using the Rose Bengal photothrombosis method, followed by transplantation of iPSC-derived cortical neurons into the area adjacent to the infarction. Behavioral recovery was assessed using the foot fault and cylinder tests. Histological analysis was performed to evaluate graft integration and neurite extension. Results: Foot fault test demonstrated significant improvements in fine motor function in the transplantation group compared to the vehicle group. However, no recovery was observed in the cylinder test, which assesses gross motor function. Neurite extension from grafted cells was observed along the corticospinal tract, with axonal projections reaching the spinal cord in 68% of transplanted mice. In addition, neurite outgrowth extended to the thalamus, superior colliculus, and vestibular nucleus, suggesting integration into multiple neural circuits. Histological analysis revealed that 16.4% and 47.3% of grafted cells expressed CTIP2 and SATB2, respectively, indicating the presence of both deep- and upper-layer cortical neurons. Conclusions: This study demonstrates that iPSC-derived cortical neurons extend axons along the corticospinal tract and can promote fine motor recovery after stroke. However, further research is needed to validate functional connectivity and long-term safety. These findings offer a promising avenue for developing cell-based therapies for stroke patients. Graphical


  • Top Cited Papers
    Open Access

    Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease

    by Nobukatsu Sawamoto, Daisuke Doi, Etsuro Nakanishi, Masanori Sawamura, Takayuki Kikuchi, Hodaka Yamakado, Yosuke Taruno, Atsushi Shima, Yasutaka Fushimi, Tomohisa Okada, et al.

    Parkinson’s disease is caused by the loss of dopamine neurons, causing motor symptoms. Initial cell therapies using fetal tissues showed promise but had complications and ethical concerns1,2,3,4,5. Pluripotent stem (PS) cells emerged as a promising alternative for developing safe and effective treatments6. In this phase I/II trial at Kyoto University Hospital, seven patients (ages 50–69) received bilateral transplantation of dopaminergic progenitors derived from induced PS (iPS) cells. Primary outcomes focused on safety and adverse events, while secondary outcomes assessed motor symptom changes and dopamine production for 24 months. There were no serious adverse events, with 73 mild to moderate events. Patients’ anti-parkinsonian medication doses were maintained unless therapeutic adjustments were required, resulting in increased dyskinesia. Magnetic resonance imaging showed no graft overgrowth. Among six patients subjected to efficacy evaluation, four showed improvements in the Movement Disorder Society Unified Parkinson’s Disease Rating Scale part III OFF score, and five showed improvements in the ON scores. The average changes of all six patients were 9.5 (20.4%) and 4.3 points (35.7%) for the OFF and ON scores, respectively. Hoehn–Yahr stages improved in four patients. Fluorine-18-l-dihydroxyphenylalanine (18F-DOPA) influx rate constant (Ki) values in the putamen increased by 44.7%, with higher increases in the high-dose group. Other measures showed minimal changes. This trial (jRCT2090220384) demonstrated that allogeneic iPS-cell-derived dopaminergic progenitors survived, produced dopamine and did not form tumours, therefore suggesting safety and potential clinical benefits for Parkinson’s disease.


  • Open Access

    Supraspinal Plasticity of Axonal Projections From the Motor Cortex After Spinal Cord Injury in Macaques

    by Satoko Ueno, Reona Yamaguchi, Kaoru Isa, Toshinari Kawasaki, Masahiro Mitsuhashi, Kenta Kobayashi, Jun Takahashi, Tadashi Isa

    During recovery following spinal cord injury in the macaque, the sensorimotor cortex on the same side as the injury (ipsilesional, unaffected) becomes activated and plays a role in guiding movements of the affected hand. Effective regulation of these movements by the ipsilesional sensorimotor cortex would depend not only on its ability to send motor commands directly to target muscles but also on coordinated functioning with higher‐level motor planning systems such as the cortico‐basal ganglia and cortico‐cerebellar loops. In this study, using anterograde viral tracers, we analyzed the axonal trajectories of corticofugal fibers from the contralesional (affected) primary motor cortex (M1) at the brainstem level in two macaque monkeys with sub‐hemisection spinal cord injury at the mid‐cervical level. They showed considerable recovery of grasping movements after injury. We found an increase in axonal projections from the contralesional M1 to the contralateral putamen, ipsilateral lateral reticular nucleus, and contralateral pontine nucleus compared to projections from the ipsilesional (unaffected) M1. We propose that these increased projections from the contralesional M1 to the striatum and precerebellar nuclei on the nondominant side may function to recruit the ipsilesional M1 through the cortico‐basal ganglia and cortico‐cerebellar loops to control hand movements on the affected side during recovery.

  • Top Cited Papers
    Open Access

    A framework for neural organoids, assembloids and transplantation studies

    by Sergiu P. Pașca, Paola Arlotta, Helen S. Bateup, J. Gray Camp, Silvia Cappello, Fred H. Gage, Jürgen A. Knoblich, Arnold R. Kriegstein, Madeline A. Lancaster, Guo-Li Ming, et al.

    As the field of neural organoids and assembloids rapidly expands, there is an emergent need for guidance and advice on designing, conducting and reporting experiments to increase the reproducibility and utility of these models. Here, our consortium– representing specialized laboratories from around the world– presents a framework for the experimental process that ranges from ensuring the quality and integrity of human pluripotent stem cells to characterizing and manipulating neural cells in vitro, and from transplantation techniques to considerations for modeling human development, evolution, and disease. As with all scientific endeavors, we advocate for rigorous experimental designs tailored to explicit scientific questions, and transparent methodologies and data sharing, to provide useful knowledge for both current research practices and for developing regulatory standards.


  • Evaluation of induced pluripotent stem cell differentiation into neural progenitor cell using Raman spectra derived from extracellular vesicles in culture supernatants

    by Kakuro Hirai, Hikaru Saito, Midori Kato, Masaharu Kiyama, Hiroko Hanzawa, Atsushi Nakane, Sayaka Sekiya, Kenji Yoshida, Akiyoshi Kishino, Atsushi Ikeda, et al.


  • Open Access

    Validation of non-destructive morphology-based selection of cerebral cortical organoids by paired morphological and single-cell RNA-seq analyses

    by Megumi Ikeda, Daisuke Doi, Hayao Ebise, Yuki Ozaki, Misaki Fujii, Tetsuhiro Kikuchi, Kenji Yoshida, Jun Takahashi


  • Open Access

    Progranulin enhances the engraftment of transplanted human iPS cell-derived cerebral neurons

    by Keitaro Yamagami, Bumpei Samata, Daisuke Doi, Ryosuke Tsuchimochi, Tetsuhiro Kikuchi, Naoya Amimoto, Megumi Ikeda, Koji Yoshimoto, Jun Takahashi

    Cerebral organoids (COs) in cell replacement therapy offer a viable approach to reconstructing neural circuits for individuals suffering from stroke or traumatic brain injuries. Successful transplantation relies on effective engraftment and neurite extension from the grafts. Earlier research has validated the effectiveness of delaying the transplantation procedure by 1 week. Here, we hypothesized that brain tissues 1 week following a traumatic brain injury possess a more favorable environment for cell transplantation when compared to immediately after injury. We performed a transcriptomic comparison to differentiate gene expression between these 2 temporal states. In controlled in vitro conditions, recombinant human progranulin (rhPGRN) bolstered the survival rate of dissociated neurons sourced from human induced pluripotent stem cell-derived COs (hiPSC-COs) under conditions of enhanced oxidative stress. This increase in viability was attributable to a reduction in apoptosis via Akt phosphorylation. In addition, rhPGRN pretreatment before in vivo transplantation experiments augmented the engraftment efficiency of hiPSC-COs considerably and facilitated neurite elongation along the host brain’s corticospinal tracts. Subsequent histological assessments at 3 months post-transplantation revealed an elevated presence of graft-derived subcerebral projection neurons—crucial elements for reconstituting neural circuits—in the rhPGRN-treated group. These outcomes highlight the potential of PGRN as a neurotrophic factor suitable for incorporation into hiPSC-CO-based cell therapies.


  • Open Access

    Stage-dependent role of interhemispheric pathway for motor recovery in primates

    by Masahiro Mitsuhashi, Reona Yamaguchi, Toshinari Kawasaki, Satoko Ueno, Yiping Sun, Kaoru Isa, Jun Takahashi, Kenta Kobayashi, Hirotaka Onoe, Ryosuke Takahashi, et al.

    Whether and how the non-lesional sensorimotor cortex is activated and contributes to post-injury motor recovery is controversial. Here, we investigated the role of interhemispheric pathway from the contralesional to ipsilesional premotor cortex in activating the ipsilesional sensorimotor cortex and promoting recovery after lesioning the lateral corticospinal tract at the cervical cord, by unidirectional chemogenetic blockade in macaques. The blockade impaired dexterous hand movements during the early recovery stage. Electrocorticographical recording showed that the low frequency band activity of the ipsilesional premotor cortex around movement onset was decreased by the blockade during the early recovery stage, while it was increased by blockade during the intact state and late recovery stage. These results demonstrate that action of the interhemispheric pathway changed from inhibition to facilitation, to involve the ipsilesional sensorimotor cortex in hand movements during the early recovery stage. The present study offers insights into the stage-dependent role of the interhemispheric pathway and a therapeutic target in the early recovery stage after lesioning of the corticospinal tract.